M K Kang1, S K Kang. 1. Department of Physiology, College of Medicine, Pusan National University, Ami-Dong, Seo-Gu, Busan, South Korea.
Abstract
INTRODUCTION: In a previous study, we observed cell proliferation 3 days after spinal cord injury, and levels of interleukin-6 (IL-6) and epidermal growth factor (EGF) had significantly increased in the region of the injury. OBJECTIVES: The purpose of the new study described here was to evaluate the roles of IL-6 and EGF after traumatic damage to the spinal cord having isolated neural progenitor cells (NPC) from adult mice. METHODS AND RESULTS: Evidence provided by the trypan blue dye exclusion assay, 5-bromodeoxyuridine immunoreactivity and Western blot analysis indicated that IL-6 and EGF induced proliferation of these spinal cord-derived NPCs via phosphorylation of Janus-activated kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) and mitogen-activated protein kinases (MAPK), respectively. Combined treatment with IL-6 and EGF accelerated proliferation of cells synergistically and phosphorylation of STAT3 and extracellular signal-regulated kinase 1/2 (Erk1/2). Furthermore, AG490 and AG1478, JAK2 inhibitor and EGFR inhibitor, respectively, prevented the IL-6- and EGF-induced proliferation of the cells. Interestingly, IL-6-activated MAPKs but EGF did not influence JAK2/STAT3 activation; AG490 specifically inhibited IL-6-induced Erk1/2 phosphorylation without affecting IL-6-induced phosphorylation of Raf and MEK1/2. These results indicate that IL-6 is directly involved in Erk1/2 activation via JAK2 and that Erk1/2 provides a signal bridge between the IL-6-induced JAK2/STAT3 pathway and EGF-induced MAPK pathway. CONCLUSIONS: Our study is the first demonstration of IL-6- and EGF-stimulated proliferation of spinal cord progenitor cells via JAK2/STAT3 and MAPK signalling pathways. These pathways play key roles in repopulation and regeneration of spinal cord tissue after injury. It may represent novel therapeutic targets for pharmacological intervention in central nervous system disease, including spinal cord injury.
INTRODUCTION: In a previous study, we observed cell proliferation 3 days after spinal cord injury, and levels of interleukin-6 (IL-6) and epidermal growth factor (EGF) had significantly increased in the region of the injury. OBJECTIVES: The purpose of the new study described here was to evaluate the roles of IL-6 and EGF after traumatic damage to the spinal cord having isolated neural progenitor cells (NPC) from adult mice. METHODS AND RESULTS: Evidence provided by the trypan blue dye exclusion assay, 5-bromodeoxyuridine immunoreactivity and Western blot analysis indicated that IL-6 and EGF induced proliferation of these spinal cord-derived NPCs via phosphorylation of Janus-activated kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) and mitogen-activated protein kinases (MAPK), respectively. Combined treatment with IL-6 and EGF accelerated proliferation of cells synergistically and phosphorylation of STAT3 and extracellular signal-regulated kinase 1/2 (Erk1/2). Furthermore, AG490 and AG1478, JAK2 inhibitor and EGFR inhibitor, respectively, prevented the IL-6- and EGF-induced proliferation of the cells. Interestingly, IL-6-activated MAPKs but EGF did not influence JAK2/STAT3 activation; AG490 specifically inhibited IL-6-induced Erk1/2 phosphorylation without affecting IL-6-induced phosphorylation of Raf and MEK1/2. These results indicate that IL-6 is directly involved in Erk1/2 activation via JAK2 and that Erk1/2 provides a signal bridge between the IL-6-induced JAK2/STAT3 pathway and EGF-induced MAPK pathway. CONCLUSIONS: Our study is the first demonstration of IL-6- and EGF-stimulated proliferation of spinal cord progenitor cells via JAK2/STAT3 and MAPK signalling pathways. These pathways play key roles in repopulation and regeneration of spinal cord tissue after injury. It may represent novel therapeutic targets for pharmacological intervention in central nervous system disease, including spinal cord injury.
Authors: A Bonni; Y Sun; M Nadal-Vicens; A Bhatt; D A Frank; I Rozovsky; N Stahl; G D Yancopoulos; M E Greenberg Journal: Science Date: 1997-10-17 Impact factor: 47.728
Authors: Elaine C Johnson; Thomas A Doser; William O Cepurna; Jennifer A Dyck; Lijun Jia; Ying Guo; Wendi S Lambert; John C Morrison Journal: Invest Ophthalmol Vis Sci Date: 2011-01-25 Impact factor: 4.799
Authors: Alexander I Chernyavsky; Juan Arredondo; Valentin Galitovskiy; Jing Qian; Sergei A Grando Journal: Am J Physiol Cell Physiol Date: 2010-07-21 Impact factor: 4.249
Authors: Bernhard T Baune; Carsten Konrad; Dominik Grotegerd; Thomas Suslow; Eva Birosova; Patricia Ohrmann; Jochen Bauer; Volker Arolt; Walter Heindel; Katharina Domschke; Sonja Schöning; Astrid V Rauch; Christina Uhlmann; Harald Kugel; Udo Dannlowski Journal: J Neuroinflammation Date: 2012-07-06 Impact factor: 8.322